Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus

Francis F Arhin; Geoffrey A McKay; Sylvain Beaulieu; Ingrid Sarmiento; Thomas R Parr Jr; Gregory Moeck

doi:10.1016/j.diagmicrobio.2009.05.022

Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus

Diagn Microbiol Infect Dis. 2009 Oct;65(2):207-10. doi: 10.1016/j.diagmicrobio.2009.05.022.

Authors

Francis F Arhin¹, Geoffrey A McKay, Sylvain Beaulieu, Ingrid Sarmiento, Thomas R Parr Jr, Gregory Moeck

Affiliation

¹ Anti-Infective Unit, The Medicines Company, St. Laurent, Quebec H4S 2A1, Canada. [email protected]

PMID: 19748436
DOI: 10.1016/j.diagmicrobio.2009.05.022

Abstract

Human serum albumin (HSA) did not affect oritavancin MICs against non-vancomycin-intermediate Staphylococcus aureus (non-VISA) strains. In time-kill assays, oritavancin bactericidal activity in the presence of HSA was significantly more rapid than comparators against non-VISA strains. HSA increased oritavancin MICs by 4-fold for VISA strains, reflective of reduced oritavancin activity in time-kill assays with HSA.

MeSH terms

Anti-Bacterial Agents / antagonists & inhibitors*
Anti-Bacterial Agents / pharmacology*
Glycopeptides / antagonists & inhibitors*
Glycopeptides / pharmacology*
Humans
Lipoglycopeptides
Microbial Sensitivity Tests
Microbial Viability / drug effects
Serum Albumin*
Staphylococcus aureus / drug effects*
Time Factors

Substances

Anti-Bacterial Agents
Glycopeptides
Lipoglycopeptides
Serum Albumin
oritavancin